A multicenter, double-blind, randomized, parallel-group, placebo-controlled and active-controlled phase III study of the efficacy and safety of quetiapine fumarate sustained-release (Seroquel) as monotherapy in the treatment of patients with MDD [major depressive disorder]
Latest Information Update: 19 Dec 2011
At a glance
- Drugs Duloxetine (Primary) ; Quetiapine (Primary)
- Indications Depression; Major depressive disorder
- Focus Registrational; Therapeutic Use
- Acronyms DIAMOND
- Sponsors AstraZeneca
- 24 Oct 2011 Results from a prespecified pooled analysis published in the International Clinical Psychopharmacology.
- 05 Dec 2007 Results have been reported at IFMAD 2007
- 31 Jul 2007 Status changed from in progress to completed.